News | August 11, 2021
Lupin posts net profit of Rs 542.46 cr. in Q1FY22
The profits were bolstered by the Boehringer Ingelheim MEK program income
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
A veteran in cell therapy and oncology commercialisation
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
